Suchergebnisse - "Tiraboschi, Juan Manuel"

PubPharm (22)

1

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy : 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)

enthalten in: EClinicalMedicine | 2024

von Paton, N. | Stöhr, W. | Arenas-Pinto, A. | +112

2

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von González-Cordón, A. | Assoumou, L. | Moyle, G. | +117

3

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk : A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Waters, L. | Assoumou, L. | González-Cordón, A. | +121

4

Determinants of long-term survival in late HIV presenters : The prospective PISCIS cohort study

enthalten in: EClinicalMedicine | 2022

von Martin-Iguacel, R. | Reyes-Urueña, J. | Bruguera, A. | +12

5

Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV

enthalten in: AIDS (London, England) | 2022

von Donadeu, L. | Tiraboschi, J. | Scévola, S. | +13

6

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

enthalten in: The Journal of antimicrobial chemotherapy | 2021

von González-Cordón, A. | Assoumou, L. | Moyle, G. | +117

7

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk : 48 week effects on subclinical cardiovascular disease

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Gonzalez-Cordon, A. | Assoumou, L. | Camafort, M. | +113

8

Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MS

enthalten in: Journal of pharmaceutical and biomedical analysis | 2020

von Rigo-Bonnin, R. | Tiraboschi, J. | Álvarez-Álvarez, M. | +6

9

Nothing is perfect : the safety issues of integrase inhibitor regimens

enthalten in: Expert opinion on drug safety | 2020

von Scévola, S. | Tiraboschi, J. | Podzamczer, D.

10

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial) : a phase 2, randomised trial

enthalten in: Lancet (London, England) | 2020

von Fidler, S. | Stöhr, W. | Pace, M. | +121

CommentIn: Lancet. 2020 Mar 14;395(10227):844-846. - PMID 32085822